Scholarlink

<p>Mesenchymal stem cells (MSCs) are a promising cell source for osteoarthritis and intervertebral disc degeneration, but their application is limited by inefficient and unstable chondrogenic differentiation. Here, nine Phorbazole D analogues were synthesized and evaluated for promoting chondrogenesis in human umbilical cord mesenchymal stem cells (hUC-MSCs) under TGF-β/dexamethasone based induction conditions. Among the tested analogues, <b>IO-5a</b> was selected for further evaluation based on its comparatively higher pro-chondrogenic activity and no detectable cytotoxicity. Image-based Alcian blue analysis showed that the positive staining area increased from approximately 17% in the control group to approximately 45% after <b>IO-5a</b> treatment. RT–qPCR further showed that 10 µM <b>IO-5a</b> upregulated COL2A1, SOX9, ACAN, and COMP by approximately 2.6-fold, 1.1-fold, 1.35-fold, and 1.4-fold, respectively. Immunofluorescence, western blotting, and 3D pellet culture analyses supported increased cartilage associated marker expression and cartilage like matrix deposition. Preliminary structure-activity relationship analysis suggested that retention of the A-ring phenolic hydroxyl group and favorable A-/C-ring substituent matching may contribute to activity. In silico target prediction and molecular docking nominated PTPN1 (PTP1B) as a potential candidate protein, although this predicted interaction requires further experimental validation. Collectively, <b>IO-5a</b> represents a bioactive Phorbazole D analogue with chondrogenesis promoting activity in hUC-MSCs.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis and biological evaluation of Phorbazole D analogues identify IO-5a as a promoter of hUC-MSC chondrogenic differentiation

  • 期刊论文

  • 发表日期：

    2026年7月30日

查看全文
  • Ai-zhu Wang,
  • Xiao-mei Liu,
  • Li-ming Zhang,
  • Lu-lu Fu,
  • Ping Li,
  • Jie-ping Zhang,
  • Hua Han

摘要

Mesenchymal stem cells (MSCs) are a promising cell source for osteoarthritis and intervertebral disc degeneration, but their application is limited by inefficient and unstable chondrogenic differentiation. Here, nine Phorbazole D analogues were synthesized and evaluated for promoting chondrogenesis in human umbilical cord mesenchymal stem cells (hUC-MSCs) under TGF-β/dexamethasone based induction conditions. Among the tested analogues, IO-5a was selected for further evaluation based on its comparatively higher pro-chondrogenic activity and no detectable cytotoxicity. Image-based Alcian blue analysis showed that the positive staining area increased from approximately 17% in the control group to approximately 45% after IO-5a treatment. RT–qPCR further showed that 10 µM IO-5a upregulated COL2A1, SOX9, ACAN, and COMP by approximately 2.6-fold, 1.1-fold, 1.35-fold, and 1.4-fold, respectively. Immunofluorescence, western blotting, and 3D pellet culture analyses supported increased cartilage associated marker expression and cartilage like matrix deposition. Preliminary structure-activity relationship analysis suggested that retention of the A-ring phenolic hydroxyl group and favorable A-/C-ring substituent matching may contribute to activity. In silico target prediction and molecular docking nominated PTPN1 (PTP1B) as a potential candidate protein, although this predicted interaction requires further experimental validation. Collectively, IO-5a represents a bioactive Phorbazole D analogue with chondrogenesis promoting activity in hUC-MSCs.

Graphical abstract